miglustat has been researched along with Acquired Language Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calì, F; Costanzo, MC; Fiumara, A; Musumeci, SA; Nicotera, AG; Vinci, M; Vitello, A | 1 |
| Caciotti, A; Deodato, F; Dionisi-Vici, C; Donati, MA; Morrone, A; Procopio, E; Rampazzo, A; Scarpa, M; Taurisano, R | 1 |
2 other study(ies) available for miglustat and Acquired Language Disorders
| Article | Year |
|---|---|
Novel compound heterozygous mutation in
Topics: 1-Deoxynojirimycin; Adult; Apathy; Brain; Cognitive Dysfunction; Corpus Callosum; Deglutition Disorders; Female; High-Throughput Nucleotide Sequencing; Humans; Intracellular Signaling Peptides and Proteins; Language Disorders; Magnetic Resonance Imaging; Mutation, Missense; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Vesicular Transport Proteins | 2020 |
The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression.
Topics: 1-Deoxynojirimycin; Adult; Age Factors; beta-Galactosidase; Cognition Disorders; Disease Progression; Female; Follow-Up Studies; Gait; Gangliosidosis, GM1; Genotype; Glycoside Hydrolase Inhibitors; Humans; Language Disorders; Motor Skills; Movement Disorders; Neuropsychological Tests; Treatment Outcome; Walking; Young Adult | 2017 |